Toll Free: 1-888-928-9744

Global Conjugate Vaccines Market (2017 - 2022) Share, Scope,Trends, Drivers, Challenges, Segmentation based on Disease Indication (PCV,Hib,DTP,Meningococcal,Others) End-user (Paediatric Vaccine, Adult Vaccine) and Geography(North America, Asia-Pacific, The Middle East and Africa, Europe and Latin America)

Published: Feb, 2019 | Pages: 124 | Publisher: Netscribes
Industry: Healthcare | Report Format: Electronic (PDF)

The market for conjugate vaccines is expected to increase, owing to global awareness about the benefits of vaccination for the prevention of certain life-threatening diseases, growing initiatives for production of low-cost vaccines, and widespread routine vaccination programmes in emerging economies. The market will witness a steady growth, expanding at a compound annual growth rate (CAGR) of 11.7% during 2017-2022, to reach approximately USD 87.7 Bn by 2022.
Disease indication segment insights:
Pneumococcal conjugate vaccine (PCV) held the largest market share (24.66%) in 2017 owing to the widespread nature of pneumococcal disease. Also, the leading vaccine-preventable cause of death among children around the world is the pneumococcal disease. Global initiatives were undertaken to speed up the introduction of pneumococcal vaccinations in low-income countries through partnerships among countries, donors, academia, international organizations, and industries. Close on its heels, the diphtheria and tetanus toxoids and pertussis (DTP) conjugate vaccine occupied a share of 23% in 2017. The higher prevalence of respiratory diseases such as whooping cough, among both children and adults, have led to the increased adoption of DTP conjugate vaccines. Haemophilus influenzae type b (Hib) conjugate vaccines are expected to grow at the fastest rate during 2017-2022.
End user segment insights:
The adult segment registered higher market share than the paediatric segment because of an increase in awareness on conjugate vaccines for adults, over the years. Still, the penetration level for adult conjugate vaccines is comparatively lower, with the lowest being for PCVs. Hence, the growth potential is very high. The paediatric vaccines, on the other hand is a stable market and depends highly on the birth rates in each region. The vaccination programmes, especially taken up by global organizations such as the United Nations Educational, Scientific and Cultural Organization (UNESCO), have been successful in eradicating many such vaccine-preventable diseases.
Regional insights:
Asia-Pacific is the largest market for conjugate vaccines, which held a share of 42%, in 2017. The primary indicators of the potential for the vaccine market is the geriatric population in the region, especially in countries such as India and China. In turn, this has, encouraged market participants to increase spending on research and development (R&D) and distribution facilities in the these countries. North America is the second biggest market for conjugate vaccines, owing to the region's widespread immunization programmes. The Middle East and Africa, and Latin America regions lack proper infrastructure and awareness of vaccine-preventable diseases, which are hindering market growth.


Companies covered:
1. GlaxoSmithKline
2. Pfizer Inc.
3. Merck & Co.
4. Novartis
5. Sanofi Pasteur
6. CSL Limited
7. Bharat Biotech International
8. Biological E Limited
9. Serum Institute of India
 Table of Contents

Chapter 1. Executive summary 1.1. Market scope and segmentation 1.2. Key questions answered 1.3. Executive summary Chapter 2. Global conjugate vaccine market - overview 2.1. Market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), geography-wise market revenue (USD Bn), and market attractiveness analysis 2.2. Market drivers 2.3. Market trends 2.4. Market challenges 2.5. Value chain analysis 2.6. Porter's five forces analysis 2.7. Segmentation based on disease indication (pneumococcal conugate vaccine (PCV), haemophilus influenzae type B (Hib) conjugate vaccine, diptheria, tetanus toxoids and pertussis (DTP) conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 2.8. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations Chapter 3. North America conjugate vaccine market 3.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 3.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 3.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations Chapter 4. Europe conjugate vaccine market 4.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 4.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 4.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations Chapter 5. Asia-Pacific conjugate vaccine market 5.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 5.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 5.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations Chapter 6. Latin America conjugate vaccine market 6.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 6.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 6.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations Chapter 7. The Middle East and Africa conjugate vaccine market 7.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 7.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 7.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations Chapter 8. Competitive landscape 8.1. GlaxoSmithKline 8.1.a. Company snapshot 8.1.b. Products/services 8.1.c. Major initiatives/highlights 8.1.d. Growth strategy 8.1.e. Geographical presence 8.1.f. Key numbers Note: Similar information areas will be covered for the remaining competitors: 8.2. Pfizer Inc. 8.3. Merck & Co. 8.4. Novartis 8.5. Sanofi Pasteur 8.6. CSL Limited 8.7. Bharat Biotech International 8.8. Biological E Limited 8.9. Serum Institute of India Chapter 9. Conclusion 9.1. Future outlook Appendix 1. List of tables 2. Research methodology 3. Assumptions 4. About Netscribes Inc.

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2065
Multi User - US $2065
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify